Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Last updated: December 31, 2024
Sponsor: University Hospital, Strasbourg, France
Overall Status: Completed

Phase

2

Condition

N/A

Treatment

Assessment of severity of ICD (impulse control disorders)

Assessment of severity of Parkinson Disease

Blood analysis

Clinical Study ID

NCT03947216
6398
  • Ages 35-75
  • All Genders

Study Summary

There is no consensus on the treatment of Impulse Control Disorder (ICD) in Parkinson Disease (PD) though it is recommended to reduce the dosage of dopamine agonists (DA).

Reduction of DA frequently leads to a worsening of motor signs (parkinsonism or dyskinesias due to the concomitant increase of levodopa doses) and non-motor signs with the appearance of a DA withdrawal syndrome (DAWS).

Chronic stimulation of the sub-thalamic nuclei may reduce ICD but is restricted to a minority of patients and cases of new-onset ICD symptoms post stimulation have been reported. The benefit of amantadine in pathological gambling is controversial and the efficacy of clozapine has been reported in a few cases but with serious safety limitations. Very recently, naltrexone did not significantly improve ICD.

Thus, an efficacious and safe treatment of ICD in PD remains an unmet need for clinical practice.

Recently, it has been reported that pimavanserin, a selective serotonin 5-HT2A inverse agonist with a satisfactory safety profile without motor side effects, was efficient in improving psychosis, insomnia and day-time sleep in PD.

Pimavanserin, marketed under the tradename NUPLAZID® was approved in 2016 by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The link between serotonin and ICD has been well established, since the enhancement of 5HT2A receptors stimulation is associated to ICD, since serotonin modulates mesolimbic dopaminergic reward system transmission and given that serotonin neurotransmission is increased during chronic intake of dopamine agonist such as pramipexole which is well-known to induce ICD in PD patients. Thus, there is a large body of evidence suggesting that the decrease of the 5HT2A activity could be efficient in reducing ICD in PD. This further supports the concept of testing the efficacy of pimavanserin (a selective 5HT2A inverse agonist) for treating ICD in PD. Our aim is to conduct a study evaluating the efficacy and safety of pimavanserin on ICD in PD.

This clinical trial is conducted with the support of the French NS-Park/FCRIN (French Clinical Research Infrastructure Network) network.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient with PD according to the UKPDSBB criteria for at least 1 year beforerandomization

  2. Patient, man or woman, aged from 35 to 75 years old

  3. Patient with moderately severe ICD assessed by QUIP-RS (each item being rated 0-16)defined as:

  • a combined ICD total score (defined as the sum of the 4 ICD sub-scores (pathological gambling + buying + hypersexuality + eating)) superior or equalto 10 or,

  • at least one of the 4 ICD sub-scores in the following range:

  1. "pathological gambling" sub-score from 6 to 12 (included),

  2. "buying" sub-score from 8 to 12 (included),

  3. "hypersexuality" sub-score from 8 to 12 (included),

  4. "eating" sub-score from 7 to 12 (included) (Weintraub et al., 2012). Theuse of "lower" margins will guarantee that the patient experiencesbehavioral disturbances severe enough to justify pimavanserin treatment.On the other hand, the use of "upper" margins will guarantee that thepatients included in the trial will not suffer from ICD severe enough toquestion ethically the use of placebo during the 8 weeks of the treatment.Eligibility of patients with QUIP-RS sub-scores above 12 will be assessedupon investigator's request by an adjudication committee composed byindependent experts external to the study (cf IX.3 AdjudicationCommittee).

  5. ICD onset after PD onset and after initiation of dopaminergic drugs

  6. Patient treated by dopaminergic drugs for at least 3 months before randomization

  7. Patient treated with a stable regimen of levodopa, dopamine agonists, COMT and MAOBinhibitors, amantadine, anticholinergic, antidepressant and benzodiazepine for atleast 1 month before the randomization and be willing to remain on the same dosesthroughout the course of their participation in the trial (Papay et al., 2014)

  8. Patient with health insurance

  9. Patient/ guardian / curator who sign the written informed consent

  10. For women of childbearing potential, use of an effective contraception method* forat least 1 month prior to randomization until 8 weeks after the last dose of studydrug administration. Women who do not have an effective contraception* must : havehad her last natural menstruation ≥24 months prior to the selection visit, or havebeen surgically sterilized prior to the selection visit, or have had a hysterectomyprior to the selection visit.

Exclusion

Exclusion Criteria:

  1. Patient suffering from another parkinsonian syndrome (multiple system atrophy,progressive supranuclear palsy, Lewy body dementia, corticobasal degeneration)

  2. Patient who have a known hypersensitivity to the study treatment, based on knownallergies to drugs of the same class

  3. Stroke, uncontrolled serious medical illness, myocardial infarction, congestiveheart failure, cardiac function disorders, within 6 months before randomization

  4. Patient with history of long QT syndrome

  5. Patient with long QTcB detected with ECG at inclusion visit (> 450 ms)

  6. Patient treated with antipsychotic drugs during the last three months beforerandomization

  7. Patient treated with concomitant medication leading to torsade de pointes (TdP)without discontinuation ≥ 5 half-lives before randomization (please refer tomedications list with known risks of TdP on appendix XVII.5.10 and check websitehttps://crediblemeds.org/index.php/tools/ for the most up-to-date information)

  8. Patient with hydro-electrolytics troubles, particularly hypokaliemia or hypocalcemianot corrected, at inclusion visit or assessed no later than 8 days beforerandomization. To be eligible, the patient's electrolyte values should be within thefollowing limits:

3.5 ≤ K+ ≤ 5 mmol/L 135 ≤ Na+ ≤ 145 mmol/L 2,20 ≤ Ca2+ ≤ 2,60 mmol/L

  1. Patient treated with a strong or moderate CYP3A4 inducer: carbamazepine, rifampicin,phenytoin, modafinil, efavirenz or a strong inhibitor of CYP3A4: azole antifungals,protease inhibitors, macrolids, without discontinuation ≥ 5 half-lives beforerandomization

  2. Patient treated with medicinal plants interacting with CYP3A4 withoutdiscontinuation ≥ 5 half-lives before randomization (Echinacea (E.pupurea,E.angustifolia and E.pallida), Piperina, Artemisia, St. John's Wort and Ginkgo

  3. Patient with Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score < 20 (to exclude patients likely with dementia) at inclusion visit (Papay et al., 2014).

  4. Patient suffering from severe depression or marked suicidal thoughts (score > 3 onthe suicidal thoughts item of the MADRS) at inclusion visit (Papay et al., 2014)

  5. History of DBS within the past year before randomization, or change in stimulationparameters less than one month prior to randomization

  6. Hematologic or solid malignancy diagnosis within 5 years prior to randomization.

[Note: Subjects with a history of localized skin cancer, basal cell or squamous cellcarcinoma, may be enrolled in the study as long as they are cancer free prior torandomization. Subjects with other localized cancers (without metastatic spread) whohave previously completed their course of treatment more than 5 years prior torandomization, are not currently receiving treatment and have been in remission maybe enrolled only if, in the opinion of the Investigator, there is no expectation forrecurrence or further cancer treatment during the study period. Antihormonal therapy (e.g., tamoxifen) is allowed if the subject's cancer is in remission and the subjectis on stable maintenance therapy to reduce their risk of recurrence.]

  1. Patient suffering from severe renal impairment define as CrCL<30 mL/min,Cockcroft-Gault at inclusion visit or assessed no later than 8 days beforerandomization

  2. Clinically significant hepatic impairment

  3. Concurrent participation in another research involving a drug or medical device

  4. Patient with language barriers precluding adequate understanding or co-operation orwho, in the opinion of the investigator, should not participate in the trial

  5. Treatment with an investigational treatment within 30 days prior to randomization

  6. Woman pregnant, nursing or of childbearing potential age without effectivecontraception methods* or intends to become pregnant.

  • an effective contraception method is defined as implants, oraloestro-progestative contraceptives or progestative which inhibit ovulationcontraceptives (e.g, desogestrel), or double barrier method (condom plusspermicide or diaphragm plus spermicide) or levonorgestrel intrauterinedevices, or vasectomized partner (confirmed with two negative spermograms).

Study Design

Total Participants: 117
Treatment Group(s): 10
Primary Treatment: Assessment of severity of ICD (impulse control disorders)
Phase: 2
Study Start date:
October 23, 2020
Estimated Completion Date:
June 17, 2024

Connect with a study center

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU d'Amien, Hopital Sud

    Amiens, 80054
    France

    Site Not Available

  • Service de Neurologie -CHU Besançon

    Besançon,
    France

    Active - Recruiting

  • Service de Neurologie and CIC -CHU Besançon

    Besançon,
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE C, Unité mouvement anormaux/Centre expert Parkinson, CHU de Lyon, Hopital neurologique Pierre Wertheimer

    Bron, 69677
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU Clermont-Ferrand, Hopital Gabriel Montpied

    Clermont-Ferrand, 63003
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, Hopital Henri Mondor

    Créteil, 94010
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Grenoble Alpes

    Grenoble, 38043
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, CHU de Lille, Hopital Roger Salengro

    Lille, 59037
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Limoges

    Limoges, 87042
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, Hopital de la Timone

    Marseille, 13385
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Nantes, Hopital Laennec

    Nantes, 44093
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE Centre Expert Parkinson Hopital de la Pitié-Salpêtrière

    Paris, 75651
    France

    Site Not Available

  • Centre d'Inverstigation Clinique, CHU de Poitiers

    Poitiers, 86021
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, CHU de REIMS

    Reims, 51100
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rennes, Hopital Pontchaillou

    Rennes, 35033
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rouen, Hopital Charles Nicolle

    Rouen, 76031
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE Unité de Mouvements Anormaux/Centre expert Parkinson, CHU de Strasbourg, Hopital de Hautepierre

    Strasbourg, 67098
    France

    Site Not Available

  • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Toulouse, Hopital Pierre-Paul Riquet

    Toulouse, 31059
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.